問卷

TPIDB > Principal Investigator

Principal Investigator


Kuang Tien General Hospital (在職)

Division of Nephrology

Division of Endocrinology

更新時間:2023-09-19

王守玠
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

9Cases

2020-04-01 - 2023-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Not yet recruiting9Sites

Terminated6Sites

2023-12-28 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-12-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2020-11-19 - 2024-12-31

Phase III

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
  • Condition/Disease

    Chronic Kidney Disease With Metabolic Acidosis

  • Test Drug

    TRC101

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

2021-01-22 - 2023-03-23

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2019-02-15 - 2021-04-22

Phase III

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites